BD (NYSE:BDX) announced that it entered into an agreement with Biocorp with the aim to use connected technology with injectable drugs.
The companies seek to track adherence for self-administered drug therapies, including biologics. They plan to integrate France-based Biocorp’s Injay technology with BD’s UltraSafe Plus passive needle guard.
Biocorp designed Injay to capture and transmit injection events using near-field communication (NFC) technology. BD developed its UltraSafe Plus passive needle guard for use with pre-fillable syringes.
Get the full story at our sister site, Drug Delivery Business News.
